Message from Ostomycure CEO, Graeme Smith.
The interest in our TIES solution for permanent ileostomy patients is growing globally. Our clinical study to prove safety and efficacy was well underway until the impact of COVID-19 halted most elective surgery in Europe.
Our strategy has been to expand the clinical sites participating in the study and we have gone from 2 sites in 1 country (UK) to negotiating with 18 sites in 4 countries (Austria, Poland, Sweden and the UK) with more pending.
“In today’s Europe of changing and stricter safety and regulatory protocols, we are committed to do whatever it takes to bring the lifestyle changing TIES ileostomy lid solution to as many people as possible. Conventional stoma options have changed very little in the last 30 years and our goal is to provide additional options for permanent ileostomy patients” stated Graeme Smith.
As soon as clinical studies are given the green light to restart in Europe OstomyCure will be ready to support sites around the EU to participate in the clinical study.Leave a reply